Skip to main content
ADC Biotechnology Limited

ADC Biotechnology Limited

ADC Biotech's patented 'Lock-Release' platform addresses problems with the development of ADCs - the Next Generation of Blockbuster Cancer Therapeutics

http://www.adcbio.com/

Tax Relief: EIS
Invest in ADC Biotechnology Limited
98% Complete
98%
Funded
£4,500,000
Target
£4,397,705
Pledged

Summary

ADC Biotechnology provides specialist drug manufacturing services based on its own patented Lock-Release™ processing technology, focused on a new wave of oncology therapeutics called antibody-drug conjugates (“ADCs”) being developed by pharmaceutical companies worldwide. ADC is already achieving revenues of £1.4m and has recently won its 90th project. 

The remit of the Company is to develop a technology platform for the efficient development & manufacture of new ‘Magic Bullet’ cancer therapies, ADCs. Application of its core Lock-Release™ technology enables maximum therapeutic effect with better patient outcomes; it considerably shortens the development timeline to clinical testing and can significantly reduce supply chain costs by maximising manufacturing yield & productivity.


You need to be registered as an investor to see further information.


Join Now

None of the information contained here or contained outside of the InvestingZone platform, including on the pitching company’s own website, in social media profiles and elsewhere constitutes part of the listing and it has not been reviewed or approved by InvestingZone or by Acceleris Capital.

You need to be registered as an investor to see further information.


Join Now

None of the information contained here or contained outside of the InvestingZone platform, including on the pitching company’s own website, in social media profiles and elsewhere constitutes part of the listing and it has not been reviewed or approved by InvestingZone or by Acceleris Capital.

You need to be registered as an investor to see further information.


Join Now

None of the information contained here or contained outside of the InvestingZone platform, including on the pitching company’s own website, in social media profiles and elsewhere constitutes part of the listing and it has not been reviewed or approved by InvestingZone or by Acceleris Capital.

You need to be registered as an investor to see further information.


Join Now

None of the information contained here or contained outside of the InvestingZone platform, including on the pitching company’s own website, in social media profiles and elsewhere constitutes part of the listing and it has not been reviewed or approved by InvestingZone or by Acceleris Capital.

You need to be registered as an investor to see further information.


Join Now

None of the information contained here or contained outside of the InvestingZone platform, including on the pitching company’s own website, in social media profiles and elsewhere constitutes part of the listing and it has not been reviewed or approved by InvestingZone or by Acceleris Capital.

You need to be registered as an investor to see further information.


Join Now

Additional information

  • Early Stage
  • Technology
  • Pharmaceuticals & Biotechnology